Company / SG&A Expense
Theriva Biologics, Inc. SG&A Expense History
FY2011-FY2011 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$2.1M
FY2011
5-year range
$2.1M / $2.1M
FY2011-FY2011
Trend
-
vs FY2010
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$2M in FY2011.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.80 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2011 | $2.1M | - |
As of FY2011 · SEC 10-K · Updated Jun 24, 2026